HGS is a direct target of miR-296 (A) Alignment of potential miR-296-binding sites in the 3' UTR of the HGS mRNA of different species. (B) pMir-Report vectors containing no 3'UTR (MCS), or containing the 3' UTR of the HGS mRNA (HGS WT) or mutated miR-296 binding sites (HGS mut1 and HGS mut2) and miR-296 or control inhibitors were co-transfected into HEK 293T cells. The inhibition of miR-296 by the anti-sense inhibitors resulted in a significant increase in luciferase signals of HGS WT and HGS mut2 but not HGS mut1 transfected cells. (C) Western blot analysis of HGS, PDGFR-β and VEGFR2 expression in HBMVECs cultured in basal medium (EBM) or HBMVECs stimulated by EGM or U87-conditioned medium. HGS expression decreased upon stimulation of HBMVECs, and PDGFR-β and VEGFR2 increased. Upon inhibition of miR-296 with anti-miR-296 molecules by transfection of HBMVECs stimulated by EGM or U87-conditioned medium, HGS expression increased, and PDGFR-β and VEGFR2 decreased. The relative blot intensities were quantified by using ImageQuant, the densitometric values normalized to β-Actin are indicated. (D)HGS, PDGFR-β and VEGFR2 expression levels under normal and angiogenic conditions. Representative images of HBMVEC immunostainings of HGS, PDGFR-β and VEGFR2 under normal (EBM) and angiogenic (EGM) conditions, size bar 20 μm. (E) Quantification of the HGS, PDGFR-β and VEGFR2 immunostaining levels, as represented in (D). Fluorescence signals were quantified using MetaVue software by analyzing at least 20 random cells per sample. (F) Silencing of HGS by siRNAs leads to increased HBMVEC tubule formation on Matrigel [size bar 300 μm], as quantified in (G) and (H). Error bars indicate S.D., **p < 0.01, ***p < 0.001, t test.